Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030305 (pancreatitis)
 16,014 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A patient who had received multiple transfusions for complications of acute hemorrhagic pancreatitis developed a potent factor V anticoagulant with bleeding due to defective hemostasis. Despite its potency, the anticoagulant disappeared within 15 days of its first manifestation. A second patient with adenocarcinoma of the colon developed an anticoagulant to factor V postoperatively after a single blood transfusion. The anticoagulants appeared to react stoichiometrically with factor V in normal plasma in vitro. They had the physicochemical properties of immunoglobulins, and their activity was neutralized by antihuman immunoglobulin antiserum. One anticoagulant appeared to be slightly more active against homologous than against autologous factor V, but it also inhibited heterologous factor V. Both anticoagulants progressively inactivated intrinsic prothrombin activator formed from normal reagents in the incubation mixture of the thromboplastin generation test, thus confirming that factor V is required for the effective action of the intrinsic prothrombin activator. Since the anticoagulants were immunoglobulins whose activity was consumed in their reaction with factor V, consumption of anticoagulant activity was used to detect factor V antigenic material in test materials. Human serum without factor V clotting activity was found to consume anticoagulant activity, i.e., to contain inactive factor V antigenic material. Plasma from two patients with hereditary factor V deficiency (parahemophilia) failed to consume significant anticoagulant activity. Thus, the lack of factor V activity in these patients represents a deficiency of factor V molecules rather than the synthesis of a defective molecule with impaired clotting activity.
 ...
PMID:Factor V anticoagulants: clinical, biochemical, and immunological observations. 419 89

Nonsteroidal anti-inflammatory drugs (NSAIDs) represent one of the most commonly used therapeutic drug groups world wide. 1.5% of the world's population is estimated as taking NSAIDs. Although NSAIDs are still generally believed to have toxic effects on the alimentary tract, some evidence of their favourable effects on the alimentary canal has recently been reported. Wider knowledge concerning these effects may allow us in the future to use NSAIDs as preventive measures in carcinoma or adenocarcinoma of the colon or even in carcinoma of the esophagus, in the treatment of motor disorders of the alimentary tract or inflammatory diseases, e.g. reflux esophagitis. The clinical studies evaluating the NSAID effects on the treatment of acute biliary colic and the short-term administration of small doses of aspirin effective in secondary prevention of cholelithiasis are also encouraging. At present the studies are being carried out to show the therapeutic action of NSAIDs in pancreatitis.
 ...
PMID:Can nonsteroidal anti-inflammatory drugs favourably affect the alimentary canal? 1289 69